Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARDTNASDAQ:CSTLNASDAQ:PGNYNASDAQ:WGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health Partners$13.14-3.0%$13.60$11.31▼$20.72$1.88BN/A384,426 shs267,142 shsCSTLCastle Biosciences$18.75-0.4%$18.31$15.45▼$35.84$541.35M1.03418,159 shs516,140 shsPGNYProgyny$21.03-2.4%$21.96$13.39▼$30.42$1.80B1.321.71 million shs819,289 shsWGSGeneDx$64.57-2.7%$78.43$24.91▼$117.75$1.84B1.94785,528 shs491,417 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health Partners0.00%-11.64%-13.84%-5.71%+1,313,999,900.00%CSTLCastle Biosciences0.00%+6.53%+13.77%-2.80%-19.60%PGNYProgyny0.00%-3.00%-4.19%+3.29%-24.13%WGSGeneDx0.00%-10.41%+1.51%-34.43%+136.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDTArdent Health Partners3.3548 of 5 stars3.50.00.00.02.60.03.1CSTLCastle Biosciences2.2581 of 5 stars3.53.00.00.01.62.50.0PGNYProgyny1.6223 of 5 stars2.21.00.00.02.72.51.3WGSGeneDx3.682 of 5 stars3.42.00.00.02.15.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDTArdent Health Partners 3.00Buy$20.6757.28% UpsideCSTLCastle Biosciences 3.00Buy$37.0097.33% UpsidePGNYProgyny 2.42Hold$23.4511.53% UpsideWGSGeneDx 2.75Moderate Buy$86.7534.35% UpsideCurrent Analyst Ratings BreakdownLatest CSTL, WGS, ARDT, and PGNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/20/2025ARDTArdent Health PartnersStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$21.00 ➝ $21.005/15/2025ARDTArdent Health PartnersRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.005/15/2025WGSGeneDxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$88.005/12/2025PGNYProgynyCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$23.00 ➝ $21.005/9/2025ARDTArdent Health PartnersGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $18.005/9/2025WGSGeneDxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$80.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.005/1/2025WGSGeneDxTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$135.00 ➝ $110.005/1/2025WGSGeneDxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$105.00 ➝ $78.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDTArdent Health Partners$6.02B0.31N/AN/AN/A∞CSTLCastle Biosciences$347.08M1.56N/AN/A$14.54 per share1.29PGNYProgyny$1.21B1.49$0.59 per share35.58$5.77 per share3.64WGSGeneDx$330.14M5.58N/AN/A$8.78 per share7.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDTArdent Health Partners$53.90M$1.638.066.70N/AN/AN/AN/A8/13/2025 (Estimated)CSTLCastle Biosciences-$57.47M-$0.1993.75N/AN/A1.95%1.47%1.27%8/4/2025 (Estimated)PGNYProgyny$62.04M$0.5736.2632.352.395.03%11.36%7.87%8/5/2025 (Estimated)WGSGeneDx-$175.77M-$1.41N/A30.89N/A-17.12%3.33%1.69%7/29/2025 (Estimated)Latest CSTL, WGS, ARDT, and PGNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PGNYProgyny$0.45$0.17-$0.28$0.17$307.86 million$324.04 million5/6/2025Q1 2025ARDTArdent Health Partners$0.21$0.29+$0.08$0.29$1.50 billion$1.50 billion5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million4/30/2025Q1 2025WGSGeneDx$0.11$0.28+$0.17-$0.23$79.90 million$87.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDTArdent Health PartnersN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/AWGSGeneDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDTArdent Health Partners0.781.911.78CSTLCastle Biosciences0.027.787.64PGNYProgynyN/A2.622.62WGSGeneDx0.252.402.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDTArdent Health PartnersN/ACSTLCastle Biosciences92.60%PGNYProgyny94.93%WGSGeneDx61.72%Insider OwnershipCompanyInsider OwnershipARDTArdent Health Partners1.70%CSTLCastle Biosciences6.50%PGNYProgyny9.40%WGSGeneDx29.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDTArdent Health Partners24,200143.04 millionN/AOptionableCSTLCastle Biosciences54028.87 million25.99 millionOptionablePGNYProgyny31085.72 million74.68 millionOptionableWGSGeneDx1,20028.53 million19.97 millionOptionableCSTL, WGS, ARDT, and PGNY HeadlinesRecent News About These CompaniesOversold Conditions For GeneDx Holdings (WGS)June 15 at 4:19 PM | nasdaq.comGeneDx, WGS, to rise 3,300% at the open - no, don’t do anything about itJune 14 at 8:47 PM | dhakatribune.comAssenagon Asset Management S.A. Lowers Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)June 14 at 4:22 AM | marketbeat.comINVESTIGATION ALERT: Edelson Lechtzin LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) and Encourages Investors with Substantial Losses to Contact the FirmJune 13 at 4:54 PM | prnewswire.com15,937 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by Harbor Capital Advisors Inc.June 13 at 3:55 AM | marketbeat.comWGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law FirmJune 12 at 5:54 PM | prnewswire.comRosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGSJune 12 at 4:20 PM | businesswire.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12 at 3:11 PM | schaeffersresearch.comGeneDx (NASDAQ:WGS) Trading Down 3.8% - Here's What HappenedJune 12 at 1:20 PM | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)June 12 at 3:39 AM | marketbeat.comWGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law FirmJune 11, 2025 | businesswire.comGeneDx Holdings Corp. (NASDAQ:WGS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 10, 2025 | marketbeat.comKevin Feeley Sells 370 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockJune 4, 2025 | marketbeat.comInsider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 370 Shares of StockJune 4, 2025 | insidertrades.comBank of America Corp DE Lowers Position in GeneDx Holdings Corp. (NASDAQ:WGS)June 4, 2025 | marketbeat.comWellington Management Group LLP Invests $10.82 Million in GeneDx Holdings Corp. (NASDAQ:WGS)June 3, 2025 | marketbeat.comSquarepoint Ops LLC Sells 34,840 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)June 2, 2025 | marketbeat.comProShare Advisors LLC Buys Shares of 3,598 GeneDx Holdings Corp. (NASDAQ:WGS)June 1, 2025 | marketbeat.comMillennium Management LLC Trims Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)May 31, 2025 | marketbeat.comTidal Investments LLC Reduces Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)May 30, 2025 | marketbeat.comAmeriprise Financial Inc. Acquires New Position in GeneDx Holdings Corp. (NASDAQ:WGS)May 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSTL, WGS, ARDT, and PGNY Company DescriptionsArdent Health Partners NYSE:ARDT$13.14 -0.41 (-3.03%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$13.15 +0.01 (+0.08%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Castle Biosciences NASDAQ:CSTL$18.75 -0.07 (-0.37%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$18.87 +0.12 (+0.64%) As of 06/13/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Progyny NASDAQ:PGNY$21.03 -0.52 (-2.41%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$20.97 -0.06 (-0.30%) As of 06/13/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.GeneDx NASDAQ:WGS$64.57 -1.80 (-2.71%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$63.50 -1.06 (-1.65%) As of 06/13/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
